TrialHepatology (Baltimore, Md.)2026

Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study.

Yameng Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.